ABSTRACT
INTRODUCTION
Adult T-cell leukemia (ATL) develops in a small portion of individuals infected with human T-cell lymphotrophic virus-1 (HTLV-I) and consists of an overabundance of malignant activated T cells, which are characterized by expression of the alpha subunit of the interleukin-2 receptor (IL-2Rα, CD25) on their cell surfaces. [1] [2] [3] [4] Presently, there is no accepted curative therapy for ATL and patients progress to death with a median survival duration of 9 months for those with acute ATL and 24 months with chronic ATL. 1 The observation that IL-2Rα is not expressed by normal resting cells, but is expressed by ATL cells, provided the rationale for the use of monoclonal antibodies (mAbs) directed toward IL-2Rα to deliver therapeutic agents. 5 Some partial and rare complete remissions were obtained in patients with ATL treated in clinical trials with the intact murine anti-Tac, humanized anti-Tac (daclizumab), as well as these intact antibodies armed with 90 Y used in an effort to develop yet more effective IL-2Rα-directed agents. 6, 7 A preclinical in vivo murine model of ATL was developed by introducing leukemic cells (MET-1) from a patient with ATL into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice and new therapeutic approaches have been tested in this model before initiating human clinical trials. [8] [9] [10] [11] [12] [13] [14] In initial studies, antibodies to IL-2Rα including daclizumab, murine anti-Tac, and 7G7/B6 inhibited the progression of the leukemia and prolonged survival of the leukemia-bearing mice. However, in general, cures were not achieved. 8 Therefore, more effective therapeutic approaches were required. In previous therapeutic trials, daclizumab was combined with pretargeted radioimmunotherapy in the ATL model and achieved the complementary actions of receptor-saturating doses of daclizumab to yield antibody-dependent cellular cytotoxicity (ADCC) and cytokine deprivationFor personal use only. on November 16, 2017 . by guest www.bloodjournal.org From mediated leukemic cell death along with the tumor cytoreduction provided by the radiation delivered to leukemic cell surfaces. 9, 10 We also demonstrated that combining daclizumab with flavopiridol, or with PS341 (velcade) significantly improved therapeutic efficacy in the ATL model. 13, 14 These observations suggest that for cancer therapy, the addition of two therapeutic agents that function via different mechanisms of action may be greater than additive in their cytotoxic action leading to malignant cell death.
In the clinical and preclinical trials, remissions have been observed using either the unmodified daclizumab monoclonal antibody at receptor-saturating doses or this antibody labeled at high specific activity with yttrium-90( 90 Y). However, the complementary actions of receptor-saturating doses of the daclizumab monoclonal antibody to yield ADCC and IL-2 deprivation mediated apoptotic leukemic cell death with this radiolabeled monoclonal antibody were difficult to obtain in conjunction with the tumor cytoreduction provided by the irradiation mediated by radionuclides such as 90 Y or 211 At delivered by daclizumab to the leukemic cell surfaces. To obtain cytokine deprivation mediated cell death one must use large receptor saturating quantities of the monoclonal antibody. However, the administration of such large quantities of monoclonal antibody armed with a radionuclide leads to low specific activity and a decreased proportion of administered radiolabeled antibody delivered and bound to tumor cells. The resulting circulating unbound radiolabeled antibody yields unacceptable bone marrow toxicity which in turn reduces the maximum dose of radioactivity that can be administered. In this study, we address the limitations inherent in the use of a single radiolabeled monoclonal antibody to simultaneously saturate receptors and to deliver a high proportion of the administered radionuclide to the tumor cells by simultaneously using 
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Another advantage of α-particles compared with β --particles is that they exhibit a low dependence on dose rate and oxygen enhancement effects. In addition, α-particles have relatively short effective path lengths in tissue that decrease the radiation delivered to normal tissues. 20, 23, 24 Among the α-emitters, currently under investigation for use in radioimmunotherapy,
211
At is perhaps the most promising candidate for radioimmunotherapeutic applications on the basis of half-life considerations (t 1/2 = 7.2h).
In this study, the therapeutic efficacy of 211 At-labeled 7G7/B6 was investigated in a murine model of ATL alone and in combination therapy with daclizumab. The scientific hypothesis supporting the use of the combination is that the two therapeutic agents 
Materials and Methods

Monoclonal antibody
7G7/B6 is a mouse IgG2a, mAb directed toward an epitope of the IL-2Rα peptide distinct from that identified by daclizumab which recognizes IL-2Rα. 25 It was reported that a murine IgG2a such as 7G7/B6 has the feature of nonspecific binding to spleen and liver that can be blocked by the administration of another murine IgG2a irrelevant antibody. 26 In this study UPC10 a murine 
N-succinimidyl N-(4-{
211 At}astatophenethyl) succinamate (SAPS). 29 Specific activities obtained for the isolated products were 2.7 and 4.6 μCi/μg respectively.
Binding integrity of radiolabeled antibody
Radiolabeling of 7G7/B6 antibody could theoretically alter its capacity to bind to the IL-2R receptor. Radiolabeled preparations were tested to determine the proportion of the radiolabeled product that bound to the IL-2Rα expressing human leukemic T-cell line Kit-225-IG3. For each preparation triplicates of 3 x10 5 , 1x10 6 , 3x10 6 Kit-225-IG3 cells were placed in PBS buffer with 10% FCS, 0.2% NaN 3 in screw cap vials. 50 μl aliquots of the radiolabeled ( 211 At) mAbs were added separately to each vial. After incubation at 4° C for 20 min, the vials were centrifuged for 4 min (setting 10) on an Eppendorf (Westbury, NY) centrifuge. The supernatant was aspirated and the radioactivity in the pellets was determined compared to a standard. Non-specific radioactivity was quantitated similarly with the exception that a 100-fold molar excess of unmodified 7G7/B6 was added to each tube. The non-specific counts were <3% of the added counts in all cases. The bind ability was measured as: (pellet counts -non-specific counts)/(initial sample counts).
Mouse model of ATL
The ATL cell population, MET-1, was established from the peripheral blood of a patient with acute ATL and the cells were maintained by serial transfer in NOD/SCID mice (Jackson Laboratories, Bar Harbor, ME performed on these mice when their serum-soluble IL-2Rα (sIL-2Rα) levels were from 1000 to 10 000 pg/ml, ~10 to 14 days post-inoculation.
Monitoring of tumor growth
Throughout the therapeutic trials, the serum concentrations of soluble human sIL-2α and human β2-microglobulin (β2μ) that were used as surrogate tumor markers were measured using ELISA kits purchased from R&D Systems (Minneapolis, MN). The ELISAs were performed as suggested in the manufacture's kit inserts.
Definition of the maximum tolerated dose
Prior to initiation of therapeutic studies, the maximum tolerated dose of 211 At-7G7/B6
was determined in non-tumor bearing NOD/SCID mice. Single doses of 6, 12, 24, 40 and 70 μCi of 211 At-7G7/B6 per mouse were administered intravenously 30 min after 400 μg of UPC10 blocking antibody given i.v. During this experiment, body weight, platelets, and white blood cells were monitored. Deaths were observed in a proportion of mice receiving doses of higher than 12 μCi. Therefore, a dose of 12 μCi of 211 At-7G7/B6 was used in the therapeutic trials.
Two mice from each group, normal control, and groups receiving 6, 12, 24, and 40
(surviving mice) μCi of 211 At-7G7/B6 had a histological examination five months after 211 At-7G7/B6 was given. Typically, the pathological evaluation of liver, kidney, intestine, lung, bone marrow, and heart were performed. Tissue samples were harvested and fixed in 10% formalin for pathological studies. The tissues were examined by a veterinary pathologist.
Therapeutic protocol
Therapeutic trials were performed in MET-1 leukemia-bearing mice with a tumor burden corresponding to sIL-2Rα values of 1 000-10 000 pg/ml. The blocking antibody UPC10
(400 μg/mouse) was given i. immunotherapy. The groups were randomly assigned and had comparable average serum concentrations of the surrogate tumor marker, sIL-2Rα (mean ~2,600 pg/ml), at the beginning of the experiments.
Statistics analysis
The serum levels of β2μ were analyzed at different time points for the different treatment groups using the student t test for unpaired data. Statistical significance of differences in survival of mice in different groups was determined by the log-rank test using the StatView program (Abacus Concepts, Berkeley, CA)
Results
Binding integrity of radiolabeled antibody
A competitive binding assay was performed following each labeling procedure. In these studies the binding of 211
At labeled 7G7/B6 antibody to IL-2Rα was specifically inhibited by unmodified 7G7/B6 at increasing concentrations (100 molar excess) using a competition assay wherein inhibition of binding of non-saturating amounts of 211 At-7G7/B6 antibody was assessed using the IL-2Rα expressing Kit-225-IG3 cell (Fig 1) . The 211 At-11F11 control antibody did not specifically bind to IL-2Rα expressing Kit-225-IG3
cell. Platelet counts were reduced in the mice receiving 211 At-7G7/B6 in a dose-related manner (Fig 2) . The nadir occurred 1 week after radiation therapy and recovered 2 to 3 weeks later. The white blood cell (WBC) count followed the same pattern as the platelet counts (Fig 3) and on the survival of ATL bearing mice (Fig 4) . 
Definition of the maximum tolerated dose and toxicity
Discussion
ATL is a malignancy of T lymphocytes with a median survival duration of 9 months in the acute form of the disease. Various combination chemotherapies have not significantly increased the survival of patients with ATL. 1 In light of the disappointing results using conventional combination chemotherapy, therapies were developed that use unmodified murine and humanized antibodies (e.g., anti-Tac, daclizumab) directed toward IL-2Rα.
Although such therapy yielded partial or complete remissions in one-third of patients, most patients subsequently suffered a disease relapse. 6, 7 The use of monoclonal antibodies armed with toxins or radionuclides specifically targeting these cytotoxic agents to leukemic cells provided a valuable augmentation of therapy. 7 There are a number of components that must be considered in designing an optimal radioimmunotherapy regimen, including (A) the selection of the antigenic target and thus the monoclonal antibody; (B) the choice of the linking agent to join the radionuclide to the monoclonal antibody; and (C) the choice of the radionuclide used.
As just noted, a pivotal issue to be addressed is the selection of the monoclonal antibody that targets the tumor and thereby the type of malignancy chosen as the target for radioimmunotherapy. In the present study, we have chosen different epitopes of the human IL-2Rα subunit identified by 7G7/B6 and daclizumab as our targets for immunotherapy. The scientific basis for this choice is that virtually no normal resting cells express the α subunit of the IL-2R, whereas this receptor is expressed by a high proportion of the abnormal cells in certain T-cell and B-cell lymphoid neoplasias, and monocytic and granulocytic leukemias identified by anti-Tac. 6 In our clinical trials, we Our prior study showed that 211 At labeled daclizumab significantly prolonged the mean survival time in cynomolgus cardiac allograft model. 33 This present study also focuses on targeting. This radionuclide is of special value for antibodies such as 7G7/B6 that have been shown to stay on the lymphocyte cell surface and to not be internalized by the target cell, a process that might lead to loss of the 211 At from its target arena.
In previous studies, we presented a pretargeting strategy with an anti-Tac antibodystreptavidin (HAT-SA) conjugate, which recognizes CD25, followed by At delivered to the leukemic cell surfaces. Indeed, whereas neither daclizumab nor 211 At-7G7/B6 alone was completely effective, remissions were observed in the majority of mice receiving both agents in conjunction (Fig 4) . when compared with those of the PBS and 211 At-11F11 control groups (P < 0.0001).
There was no significant difference in ß 2 µ levels between the group receiving a single dose of 12 µCi 211 At-11F11 and that receiving PBS (P = 0.43). 
